explore -WSS

explore

author：comprehensive 2025-09-27 18:22:28 - browse：66

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Pancreatic cancer early detection could be helped by AI

focus

hotspot

WSS

In search for therapies for solid tumors, companies turn to claudin

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Boston competes with Raleigh

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Obesity now affects over 1 billion people worldwide, study finds

Readout Newsletter: The latest on Novavax, Merck, Bluebird

entertainment

explore

knowledge

Wildfire smoke exposes gaps in outdoor worker protections

How to address the problem of discarded donor organs

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

AstraZeneca loses challenge to Medicare drug price negotiation

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

The Affordable Care Act has saved billions in health care costs

Guidelines to prevent youth baseball injuries need more muscle

Why getting cancer drugs just got harder for rural patients

Alkermes shareholders re

Wegovy leads to weight loss. Can it treat depression, too?

hotspot

FTC sues over Novant Health acquisition of two N.C. hospitals

Congress gives doctors Medicare pay bump

Medicare Advantage insurers face 0.2% cut to 2025 payments

FDA does about

Biotech companies concerned about China biosecurity crackdown

Medicare Advantage insurers face 0.2% cut to 2025 payments

focus

focus

hotspot

focus